ADMA Biologics Inc (ADMA)
Working capital turnover
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue (ttm) | US$ in thousands | 426,454 | 382,809 | 330,245 | 283,177 | 258,216 | 234,293 | 208,108 | 181,890 | 154,079 | 130,481 | 110,072 | 93,998 | 80,944 | 68,517 | 58,112 | 48,069 | 42,220 | 40,301 | 37,248 | 36,021 |
Total current assets | US$ in thousands | 331,410 | 318,193 | 303,691 | 276,419 | 257,013 | 273,699 | 266,243 | 264,086 | 270,402 | 224,095 | 222,774 | 239,800 | 208,729 | 174,785 | 171,355 | 177,277 | 153,741 | 139,549 | 142,990 | 165,488 |
Total current liabilities | US$ in thousands | 55,542 | 44,891 | 44,177 | 53,088 | 49,806 | 41,841 | 41,952 | 36,728 | 39,267 | 44,440 | 28,072 | 31,567 | 30,378 | 32,337 | 18,186 | 21,206 | 19,947 | 16,474 | 12,880 | 13,908 |
Working capital turnover | 1.55 | 1.40 | 1.27 | 1.27 | 1.25 | 1.01 | 0.93 | 0.80 | 0.67 | 0.73 | 0.57 | 0.45 | 0.45 | 0.48 | 0.38 | 0.31 | 0.32 | 0.33 | 0.29 | 0.24 |
December 31, 2024 calculation
Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $426,454K ÷ ($331,410K – $55,542K)
= 1.55
The working capital turnover ratio for ADMA Biologics Inc has shown a steady increase over the past few years, indicating improved efficiency in the company's working capital management. From March 31, 2020, to December 31, 2024, the ratio has increased from 0.24 to 1.55.
A higher working capital turnover ratio signifies that the company is generating sales revenue more efficiently with the available working capital. This improvement could be attributed to better inventory management, faster collections of accounts receivables, or more efficient payment of accounts payable.
The consistent upward trend in the working capital turnover ratio suggests that ADMA Biologics Inc has been able to optimize its working capital levels, leading to increased operational efficiency and potentially higher profitability. This reflects positively on the company's financial health and management's ability to efficiently utilize its resources.
Peer comparison
Dec 31, 2024